Hyperphosphatemia - Pipeline Review, H1 2020
Hyperphosphatemia - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides an overview of the Hyperphosphatemia (Nutritional Disorders) pipeline landscape.
Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperphosphatemia (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperphosphatemia (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hyperphosphatemia (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides an overview of the Hyperphosphatemia (Nutritional Disorders) pipeline landscape.
Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperphosphatemia (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperphosphatemia (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hyperphosphatemia (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia (Nutritional Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperphosphatemia (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperphosphatemia (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia (Nutritional Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hyperphosphatemia - Overview
Hyperphosphatemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperphosphatemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperphosphatemia - Companies Involved in Therapeutics Development
3SBio Inc
Ardelyx Inc
China Nuokang Bio-Pharmaceutical Inc
Chugai Pharmaceutical Co Ltd
Citragen Pharmaceuticals Inc
J-Pharma Co Ltd
OPKO Health Inc
Panion & Bf Biotech Inc
Shield Therapeutics Plc
Unicycive Therapeutics Inc
Vidasym Inc
Hyperphosphatemia - Drug Profiles
CGN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colestilan chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EOS-789 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fermagate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPH-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanthanum polystyrene sulfonate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Hyperphosphatemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UNI-494 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperphosphatemia - Dormant Projects
Hyperphosphatemia - Discontinued Products
Hyperphosphatemia - Product Development Milestones
Featured News & Press Releases
Jun 15, 2020: Ardelyx announces positive second data analysis from ongoing NORMALIZE phase 4 study evaluating Tenapanor in CKD patients on dialysis
Dec 04, 2019: Ardelyx reports positive data from tenapanor’s Phase III CKD trial
Nov 06, 2019: Ardelyx announces presentation at Kidney Week 2019
Oct 15, 2019: Akebia files lawsuit against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia for its Iron Deficiency Anemia Indication and imposing a prior authorization requirement for its Hyperphosphatemia indication
Sep 03, 2019: Ardelyx announces positive results from the pivotal phase 3 AMPLIFY study evaluating tenapanor in dialysis patients who have uncontrolled hyperphosphatemia despite phosphate binder treatment
Mar 07, 2019: Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Feb 07, 2019: Ardelyx collaboration partner, Kyowa Hakko Kirin, announces initiation of a phase 2 clinical study of Tenapanor for Hyperphosphatemia patients on dialysis in Japan
Oct 26, 2018: Ardelyx presents new preclinical data demonstrating synergy between Tenapanor and Sevelamer when dosed in combination for elevated serum phosphorus
Aug 29, 2018: Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
May 21, 2018: Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
Nov 21, 2017: Ardelyx Announces Updated Development Path for Tenapanor
Apr 18, 2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings
Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
Jan 06, 2017: Shield Therapeutics Provides Update on PT20
Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hyperphosphatemia - Overview
Hyperphosphatemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperphosphatemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperphosphatemia - Companies Involved in Therapeutics Development
3SBio Inc
Ardelyx Inc
China Nuokang Bio-Pharmaceutical Inc
Chugai Pharmaceutical Co Ltd
Citragen Pharmaceuticals Inc
J-Pharma Co Ltd
OPKO Health Inc
Panion & Bf Biotech Inc
Shield Therapeutics Plc
Unicycive Therapeutics Inc
Vidasym Inc
Hyperphosphatemia - Drug Profiles
CGN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colestilan chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EOS-789 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fermagate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPH-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanthanum polystyrene sulfonate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Hyperphosphatemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UNI-494 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperphosphatemia - Dormant Projects
Hyperphosphatemia - Discontinued Products
Hyperphosphatemia - Product Development Milestones
Featured News & Press Releases
Jun 15, 2020: Ardelyx announces positive second data analysis from ongoing NORMALIZE phase 4 study evaluating Tenapanor in CKD patients on dialysis
Dec 04, 2019: Ardelyx reports positive data from tenapanor’s Phase III CKD trial
Nov 06, 2019: Ardelyx announces presentation at Kidney Week 2019
Oct 15, 2019: Akebia files lawsuit against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia for its Iron Deficiency Anemia Indication and imposing a prior authorization requirement for its Hyperphosphatemia indication
Sep 03, 2019: Ardelyx announces positive results from the pivotal phase 3 AMPLIFY study evaluating tenapanor in dialysis patients who have uncontrolled hyperphosphatemia despite phosphate binder treatment
Mar 07, 2019: Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Feb 07, 2019: Ardelyx collaboration partner, Kyowa Hakko Kirin, announces initiation of a phase 2 clinical study of Tenapanor for Hyperphosphatemia patients on dialysis in Japan
Oct 26, 2018: Ardelyx presents new preclinical data demonstrating synergy between Tenapanor and Sevelamer when dosed in combination for elevated serum phosphorus
Aug 29, 2018: Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
May 21, 2018: Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
Nov 21, 2017: Ardelyx Announces Updated Development Path for Tenapanor
Apr 18, 2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings
Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
Jan 06, 2017: Shield Therapeutics Provides Update on PT20
Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Hyperphosphatemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hyperphosphatemia - Pipeline by 3SBio Inc, H1 2020
Hyperphosphatemia - Pipeline by Ardelyx Inc, H1 2020
Hyperphosphatemia - Pipeline by China Nuokang Bio-Pharmaceutical Inc, H1 2020
Hyperphosphatemia - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Hyperphosphatemia - Pipeline by Citragen Pharmaceuticals Inc, H1 2020
Hyperphosphatemia - Pipeline by J-Pharma Co Ltd, H1 2020
Hyperphosphatemia - Pipeline by OPKO Health Inc, H1 2020
Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H1 2020
Hyperphosphatemia - Pipeline by Shield Therapeutics Plc, H1 2020
Hyperphosphatemia - Pipeline by Unicycive Therapeutics Inc, H1 2020
Hyperphosphatemia - Pipeline by Vidasym Inc, H1 2020
Hyperphosphatemia - Dormant Projects, H1 2020
Hyperphosphatemia - Discontinued Products, H1 2020
Number of Products under Development for Hyperphosphatemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hyperphosphatemia - Pipeline by 3SBio Inc, H1 2020
Hyperphosphatemia - Pipeline by Ardelyx Inc, H1 2020
Hyperphosphatemia - Pipeline by China Nuokang Bio-Pharmaceutical Inc, H1 2020
Hyperphosphatemia - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Hyperphosphatemia - Pipeline by Citragen Pharmaceuticals Inc, H1 2020
Hyperphosphatemia - Pipeline by J-Pharma Co Ltd, H1 2020
Hyperphosphatemia - Pipeline by OPKO Health Inc, H1 2020
Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H1 2020
Hyperphosphatemia - Pipeline by Shield Therapeutics Plc, H1 2020
Hyperphosphatemia - Pipeline by Unicycive Therapeutics Inc, H1 2020
Hyperphosphatemia - Pipeline by Vidasym Inc, H1 2020
Hyperphosphatemia - Dormant Projects, H1 2020
Hyperphosphatemia - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Hyperphosphatemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
3SBio Inc
Ardelyx Inc
China Nuokang Bio-Pharmaceutical Inc
Chugai Pharmaceutical Co Ltd
Citragen Pharmaceuticals Inc
J-Pharma Co Ltd
OPKO Health Inc
Panion & Bf Biotech Inc
Shield Therapeutics Plc
Unicycive Therapeutics Inc
Vidasym Inc
Number of Products under Development for Hyperphosphatemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
3SBio Inc
Ardelyx Inc
China Nuokang Bio-Pharmaceutical Inc
Chugai Pharmaceutical Co Ltd
Citragen Pharmaceuticals Inc
J-Pharma Co Ltd
OPKO Health Inc
Panion & Bf Biotech Inc
Shield Therapeutics Plc
Unicycive Therapeutics Inc
Vidasym Inc
